Blueprint Medicines Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Net Income	-506.98	-557.52	-644.09	313.88	-347.69	-236.64	-148.12	-72.5	-55.92	-46.05	Upgrade
Depreciation & Amortization	20.77	20.1	12.79	12.35	10.25	4.25	1.58	1.58	0.95	0.62	Upgrade
Share-Based Compensation	92.67	98.97	91.63	75.53	54.65	30.53	12.52	6.14	5.18	2.33	Upgrade
Other Operating Activities	-43.31	-63.83	241.02	-14.72	4.78	26.85	14.15	40.26	14.97	1.94	Upgrade
Operating Cash Flow	-436.85	-502.28	-298.65	387.04	-278.02	-175.01	-119.87	-24.51	-31.68	-35.4	Upgrade
Capital Expenditures	-16.06	-8.92	-3.09	-3.16	-14.01	-12.68	-15.51	-2.35	-4.88	-0.7	Upgrade
Acquisitions	0	0	-258.15	0	0	0	0	0	0	0	Upgrade
Change in Investments	290.1	-140.33	35.38	-431.09	-2.45	-148.41	-56.84	-216.47	0	0	Upgrade
Other Investing Activities	-	-0.29	-	-	-	-	-	-	-1.2	-	Upgrade
Investing Cash Flow	274.04	-149.54	-225.86	-434.25	-16.47	-161.09	-72.35	-218.82	-6.08	-0.7	Upgrade
Share Issuance / Repurchase	21.34	8.2	50.72	617.76	340.75	6.43	547.5	136.05	157.07	0.27	Upgrade
Debt Issued / Paid	97.93	137.79	0	0	0	-1.53	-2.58	-3.33	-1.81	6.23	Upgrade
Other Financing Activities	-0.04	415.83	-	-	-0.12	-0.44	-0.97	-0.14	-2.05	74.85	Upgrade
Financing Cash Flow	119.23	561.81	50.72	617.76	340.64	4.45	543.95	132.58	153.22	81.35	Upgrade
Exchange Rate Effect	0.2	-0.21	-0.89	-0.35	0.02	0	0	0	0	0	Upgrade
Net Cash Flow	-43.58	-90.01	-473.8	570.55	46.16	-331.64	351.74	-110.76	115.47	45.25	Upgrade
Free Cash Flow	-452.91	-511.2	-301.74	383.88	-292.03	-187.69	-135.38	-26.87	-36.56	-36.1	Upgrade
Free Cash Flow Margin	-181.61%	-250.54%	-167.56%	48.36%	-439.06%	-421.57%	-631.84%	-96.74%	-320.69%	-	Upgrade
Free Cash Flow Per Share	-7.48	-8.57	-5.16	7.04	-6.11	-4.28	-3.58	-0.98	-2.00	-25.41	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).